The Study of Serum Prostate Specific Antigen and Phosphatase Isoenzymes Activity as Diagnostic Parameters in Patients with Prostate Cancer in Nigeria

Chidi Uzoma, Igwe and Chidiebere Ikechukwu, Ikaraoha and Jaye Olasumbo, Ogunlewe and Gilbert Obiora, Nwobu and Livinus Ariri Donatus, Duru and Azukaego Thomas Hughs, Mokogwu (2004) The Study of Serum Prostate Specific Antigen and Phosphatase Isoenzymes Activity as Diagnostic Parameters in Patients with Prostate Cancer in Nigeria. [Journal (On-line/Unpaginated)]

Full text available as:



Serum activities of Acid Phosphatase (ACP) and Prostatic Acid Phosphatase (PAP) are still employed in most hospitals in Nigeria for the diagnosis of prostate cancer, because of lack of resources for prostate specific antigen (PSA) assay. Serum PSA and activities of phosphatase isoenzymes ACP and PAP, Alkaline Phosphatase (ALP) and Heat stable Alkaline Phosphatase (HSAP) were studied in 71 apparently healthy male controls and 47 proven prostate cancer patients. There were statistically significant increases in the mean serum levels of PSA, PAP, ACP, ALP and HSAP in the prostate cancer patients compared to the controls (P<0.001). PSA level was increased above the cut-off level in 85.1% of patients, PAP in 66.0%, ACP in 57.5%, ALP in 34.0% and HSAP in 21.3% of cases. Serum levels of PSA, ACP and PAP were lower and of ALP and HSAP higher in patients with longer duration of the disease (P<0.05). The study confirms the relevance of PSA assay over ACP, PAP, ALP and HSAP in the diagnosis of prostate cancer patients. It highlights the need for the inclusion of PSA assay in hospitals for accurate diagnosis of prostatic carcinoma.

Item Type:Journal (On-line/Unpaginated)
Keywords:Prostate Cancer, Prostate specific antigen, Acid phosphatase, Nigeria
Subjects:JOURNALS > Online Journal of Health and Allied Sciences
ID Code:3899
Deposited By: Kakkilaya Bevinje, Dr. Srinivas
Deposited On:22 Oct 2004
Last Modified:11 Mar 2011 08:55

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

1. Pienta KJ, Demers R, Holf M, Kan TY, Motie JE, Severson RK. Effects of age and race on the survival of men with prostrate cancer in the Metropolitan Detroit tricounty area, 1973 to 1987. Urology. 1995;45:93-101.

2. Ahluwalia BS, Jackson MA, Jones GW, William AO, Rao MS, Rajguru S. Blood hormone profiles in prostate cancer patients in high-risk and low – risk population. Cancer. 1981;48:2267-2273.

3. Osegbe DN. Prostate cancer in Nigerians: facts and non -facts. J Urol. 1997;157:1340-1343.

4. Ogunbiyi JO., Shittu OB. Increased incidence of prostate cancer in Nigerians. J Natt Med Assoc. 1999;91:159-164.

5. Sun T, Lam KW, Narukor L. Clinical applicability of acid phosphatase isoenzyme assay. Clin Chem. 1981;27:1742-1744.

6. Morote RJ, de Torres MJA. Determination of prostatic specific antigen and prostatic acid phosphatase as tumour markers of cancer of the prostate. Arch Esp Urol. 1989;42:124-130.

7. Eke N, Sapira MK. Prostate cancer in Port Harcourt, Nigeria: features and out come. Urology. 2002;4:1-2.

8. Slack NH, Chu TM, Wajsman LZ, Murphy GP. Carcinoplacental isoenzyme (Regan) in carcinoma of the prostate. National prostate cancer project. 1981;41:146-151.

9. Schmidt JD, Slack NH, Chu TM, Murphy GP. Placenta – like isoenzyme of alkaline phosphate in prostatic cancer. J Urol 1982;127:457–459.

10. Moss DW, Henderson A, Kachmar JF. Enzymes. In Tietz NW. ed. Fundamentals of Clinical Chemistry. Philadelphia: WB Saunders Co, 1987. pp310-313, 329-332.

11. Moss DW, Whitby LG. A simplified heat inactivated method for investigating alkaline phosphatase isoenzymes in serum. Clin Chem Acta 1975;61:63–71.

12. Varley H, Gowenlock AH, Bell H. Enzymes. In William H ed. Practical Clinical Biochemistry. London: William Heinemann Med Books Ltd, 1980. p 813–818.

13. Vashi AR, Wojno KJ, Henicks W, England BA, Vessella RL, Lange PH, et. al. Determination of the "reflex range" and appropriate cut-points for percent free prostate-specific antigen in men referred for prostatic evaluation using the AxSYM system. Urology. 1997;49:19-27.

14. Dupont A, Cusan L, Gomez JL, Thibeault MM, Tremblay M, Labrie F. Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate. J Urol. 1991;146:1064-1068.

15. Nduka N. Clinical Biochemistry for Students of Pathology. Longman Nigeria Plc, Nigeria. 1999; 225-228.

16. Bauer HW. Acid phosphatase, alkaline phosphatase and prostate – specific antigen: usefulness in diagnosis of metastatic disease and follow–up. Prog Clin Biol Res. 1988;269:33–42.

17. Way BA, Kesseler G. Tumour marker overview. Laboratory Medicine Newsletter. 1996; 4: 9.

18. Ekwere PD, Egbe SN. The changing pattern of prostate cancer in Nigerians: current status in the southeastern states. J Natl Med Assoc. 2002;94:619-627.

19. Gadre SG, Kale KU, Hedge R, Raste AS. Comparative study of alkaline phosphatase and prostate specific antigen in prostate cancer. Indian J Med. Sci. 2000;54:136-139.

20. Wajsman Z, Chu TM, Bross D, Saroff J, Murphy GP, Johnson DE, Scott WA, Gibbons RP, Prout GR, Schmidt JD. Clinical significance of serum alkaline phosphatase isoenzymes levels in advanced prostate carcinoma. J Urol. 1978;244-246.

21. Tucci A, Saviano C, Del-Prete S. Role of alkaline phosphatase Regan isoenzyme in prognosis of patients with osteosarcoma. Medicina (firenze). 1990;10:158-160.

22. Filella X, Molina R, Jo J, Umbert B, Bedini JL, Ballesta AM. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer. Tumour Biol. 1990;11:289-294.


Repository Staff Only: item control page